- ►duanessolution.com K Kriechbaum, S Michels, F Prager, M … - British Journal of Ophthalmology, 2008 - bjo.bmj.com Results: Mean baseline central retinal thickness (CRT) in OCT was 558 µm (range
353–928 µm) and mean BCVA was 20/100. One day after the first injection, CRT
significantly decreased to 401 μm (p<0.01). Three injections reduced ... Cited by 38 - Related articles - BL Direct - All 8 versions
TC Kreutzer, CS Alge, AH Wolf, D Kook, J … - British Medical Journal, 2008 - bjo.bmj.com Results: Patients presented at a mean age of 69 years (range 44–86). Mean
duration of symptoms was 40 weeks (range 1–300). Mean (SD) VA at baseline was
0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = ... Cited by 26 - Related articles - BL Direct - All 3 versions
MD RABENA, DJ PIERAMICI, AA … - Retina, 2007 - journals.lww.com Dr. Pieramici has received research, consulting, or advisory fees from the
following pharmaceutical companies: Eyetech, Genentech, QLT, and Neovista. Dr.
Avery has received consulting or advisory fees from the following ... Cited by 71 - Related articles - BL Direct - All 3 versions
MM Moschos, M Moschos - Documenta ophthalmologica, 2008 - Springer Abstract Purpose To evaluate by multifocal electroretinography (MFERG) and
optical coherence tomography (OCT) the effectiveness of intravitreal use of
bevacizumab (Avastin) in the treatment of macular edema due to central ... Cited by 14 - Related articles - BL Direct - All 2 versions
DC Ferrara, H Koizumi, RF Spaide - American Journal of Ophthalmology, 2007 - Elsevier Six eyes of five consecutive patients with CRVO treated with intravitreal
bevacizumab injection were reviewed retrospectively. The patients did not have
other ocular conditions that could have compromised visual acuity. The mean ... Cited by 26 - Related articles - All 27 versions
H Noma, H Funatsu, M Yamasaki, H Tsukamoto … - Eye, 2006 - nature.com Aqueous and vitreous samples were obtained during cataract and vitreous surgery
from 24 patients (24 eyes) with macular oedema in BRVO. The VEGF and IL-6 levels
in aqueous humour, vitreous fluid, and plasma were determined by ... Cited by 21 - Related articles - BL Direct - All 3 versions
A Stahl, H Agostini, LL Hansen, N Feltgen - Graefe's Archive for Clinical and Experimental …, 2007 - Springer Abstract Background Macular edema is the main reason for de- creased visual
acuity (VA) in early retinal vein occlusion (RVO). Bevacizumab (Avastin,
Genentech) is an anti- VEGF substance to treat macular edema triggered by ... Cited by 50 - Related articles - BL Direct - All 3 versions
GB Jaissle, M Leitritz, F Gelisken, F … - Graefe's Archive for Clinical and Experimental …, 2009 - Springer Page 1. RETINAL DISORDERS One-year results after intravitreal bevacizumab therapy
for macular edema secondary to branch retinal vein occlusion ... Cited by 19 - Related articles - All 2 versions
